Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide

Leukemia and Lymphoma

Volumn 52, Issue 5, 2011, Pages 776-785

  Offidani, Massimo ^a   Corvatta, Laura ^b   Polloni, Claudia ^a   Gentili, Silvia ^a   Brioni, Annamaria ^c   Visani, Giuseppe ^b   Galieni, Piero ^b   Brunori, Marino ^b   Alesiani, Francesco ^b   Catarini, Massimo ^b   Centurioni, Riccardo ^b   Samori, Arduino ^b   Blasi, Nicola ^b   Ferranti, Mario ^b   Fraticelli, Paolo ^b   Mele, Anna ^b   Rizzi, Rita ^d   Larocca, Federica ^e   Leoni, Pietro ^a  

^a OSPEDALI RIUNITI   (Italy)

^b GEMaMM   (Italy)

^c Istituto di Ematologia Seragnoli   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

antibiotic; infection; Multiple myeloma; prophylaxis; thalidomide

Indexed keywords

BORTEZOMIB; COTRIMOXAZOLE; DEXAMETHASONE; DOXORUBICIN; LOW MOLECULAR WEIGHT HEPARIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THALIDOMIDE; WARFARIN;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; FEMALE; HUMAN; INFECTION RISK; INFECTIOUS COMPLICATION; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEPTIC SHOCK; THROMBOCYTE COUNT; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OPPORTUNISTIC INFECTIONS; PROBABILITY; RETROSPECTIVE STUDIES; THALIDOMIDE; VENOUS THROMBOSIS;

EID: 79955065301     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.555027     Document Type: Article

References (35)

1. Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clinic Proc 1975;50:29-40.
2. Oshima K, Kanda Y, Nannya Y, et al. Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. Am J Hematol 2001;67:1-5. (Pubitemid 32336696)
3. Augustson BM, Begun G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23:9219-9226.
4. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009;49:1211-1225.
5. Mills KH, Cawley JC. Abnormal monoclonal antibody-defined helper/suppressor T-cell subpopulations in multiple myeloma: relationship to treatment and clinical stage. Br J Haematol 1983;53:271-275. (Pubitemid 13171501)
6. Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006;107:301-304. (Pubitemid 43053555)
7. Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001;98:2992-2998.
8. Ries LA, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005 [Internet]. Available from: www.seer.cancer.gov
9. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-436. (Pubitemid 46630462)
10. Ludwig H, Hajek R, Tóthová E, et al. Thalidomide- dexamethasone compared to melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009;113: 3435-3442.
11. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-381.
12. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomde versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma. Lancet 2007;370: 1209-1218. (Pubitemid 47516593)
13. Offidani M, Corvatta L, Piersantelli MN, et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006;108:2159-2164. (Pubitemid 44497495)
14. Zervas K, Mihou D, Katodritou E, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group. Ann Oncol 2007;18:1369-1375. (Pubitemid 47305012)
15. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821.
16. Cesana C, Nosari AM, Klersy C, et al. Risk factors for the development of bacterial infections in patients with multiple myeloma treated with two different vincristine-adriamycindexamethasone schedules. Haematologica 2003;88:1022-1028. (Pubitemid 37151153)
17. Facon T, Mary JY, Pégourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006;107:1292-1298. (Pubitemid 43242361)
18. Hernandez JM, Garcia-Sanz R, Golvano E, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004;127: 159-164. (Pubitemid 39371808)
19. Shustik C, Belch A, Robinson S, et al. A randomized comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 2007;136:203-211. (Pubitemid 46020747)
20. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068-1075. (Pubitemid 44208634)
21. Haslett PA, Corral LG, Albert M, et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187:1885-1892. (Pubitemid 28262451)
22. Haslett PA, Hanekom WA, Muller G, et al. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 2003;187:946-955. (Pubitemid 36337907)
23. Blanco B, Perez-Simon JA, Sanchez-Abarca LI, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006;107:3575-3583.
24. Heider U, Rademacher J, Kaiser M, et al. Decrease in CD4+ T cells in multiple myeloma patients receiving bortezomib. Blood 2009;114(Suppl. 1): Abstract 3865.
25. Nucci M, Anaissie E. Infections in patients with multiple myeloma. Semin Hematol 2009;46:277-288.
26. Hargreaves RM, Lea JR, Griffiths H, et al. Immunological factors and risk of infection in plateau phase myeloma. J Clin Pathol 1995;48:260-266.
27. Perri RT, Hebbel RP, Oken MM. Influence of treatment and response status on infection risk in multiple myeloma. Am J Med 1981;71:935-940. (Pubitemid 12191973)
28. Savage DG, Lindenbaumn J, Garret TJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med 1982;96:47-50. (Pubitemid 12205515)
29. Nelson S. Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Chest 2001;119:419S-425S. (Pubitemid 32163812)
30. Juffermans NP, Verbon A, Schultz MJ, et al. Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens. Antimicrob Agents Chemother 2001;45:1547-1549. (Pubitemid 32374132)
31. Horvath CJ, Ferro TJ, Jesmok G, et al. Recombinant tumor necrosis factor increases pulmonary vascular permeability independent of neutrophils. Proc Natl Acad Sci USA 1988;85:9219-9223. (Pubitemid 19001868)
32. Zhang P, Summer WR, Bagby GJ, et al. Innate immunity and pulmonary host defense. Immunol Rev 2000;173:39-51. (Pubitemid 30095209)
33. Kroger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006;17:297-303. (Pubitemid 43160121)
34. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110:2339-2346. (Pubitemid 350100757)
35. Weill-Engerer S, Meaume S, Lahlou A, et al. Risk factor for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study. J Am Geriatr Soc 2004;52: 1299-1304. (Pubitemid 39038202)